ReviewViruses2026
Modulation of DNA Damage by Epstein-Barr Virus (EBV).
Review in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Epstein-Barr Virus (EBV) is an oncogenic gammaherpesvirus present in >95% of the adult population. EBV is responsible for nearly 2% of the global cancer burden and is a contributing factor in the development and progression of both epithelial and lymphoid malignancies. Throughout its lifecycle, EBV manipulates the DNA Damage Response (DDR). Aberrations in the DDR pathway result in genomic instability, a hallmark of cancer. In this review, we explore how EBV gene products expressed during lytic reactivation and latency promote genomic instability by creating a genotoxic environment and interacting with components of the DDR. Additionally, we describe viral genes capable of suppressing critical checkpoints which facilitate repair of damaged DNA. The ultimate failsafe in the case of catastrophic DNA damage is senescence or cell death, processes which are suppressed by EBV gene products. We also discuss how EBV appropriates DDR machinery to replicate its own genome during lytic reactivation. The manipulation of DDR proteins is essential for EBV-induced immortalization of primary B-cells infected in vivo, and viral strains engineered to lack these genes show reduced or ablated transformation efficacy, demonstrating the critical role of the DDR in EBV-induced oncogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.